Close Menu

NEW YORK – NeuMoDx announced Monday its multiplex RT-PCR SARS-CoV-2 test received CE marking.

The NeuMoDx SARS-CoV-2 Assay detects SARS-CoV-2 RNA from the Nsp2 gene and N gene in nasopharyngeal, oropharyngeal, or nasal swab specimens. The test runs on the NeuMoDx 288 and 96 Molecular Systems with results in 80 minutes from primary collection or daughter tubes, the company said. The systems can run up to 288 patient samples and can be used by laboratories to validate their own laboratory-developed tests, NeuMoDx added. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.